Articles from Ossium Health

Ossium Health, a clinical-stage bioengineering company with a first-of-its-kind bone marrow bank for processing and deploying stem cell-based therapies, today announced that it will be hosting a booth at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition being held December 7-10, 2024, in San Diego, CA.

Ossium Health, a commercial-stage bioengineering company with the first-of-its-kind bone marrow bank for processing and deploying stem cell-based therapies, today announced the signing of a contract with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services, to advance the company’s ready-to-use bone marrow for national emergency preparedness. The contract, initially funded at $21 million for its base period, has the potential to reach a total value of $125 million with additional options spanning five years.

Ossium Health, a clinical-stage bioengineering company that built a first-of-its-kind organ donor-derived bone marrow bank, today announced from the North American Spine Society (NASS) Annual Meeting that OssiGraft Prime™ has won the highly coveted Spine Technology Award from Orthopedics This Week. The award recognizes groundbreaking advancements in spine surgery products and honors the engineering teams and inventors behind these innovations.

Ossium Health, a clinical-stage bioengineering company that built a first-of-its-kind organ donor-derived bone marrow bank to deploy hematopoietic stem cells for blood cancer treatment, today announced positive preliminary outcomes for its first leukemia patient.

Ossium Health, a bioengineering company that entered the orthobiologics field in 2023, announced the first surgery using its next-generation viable bone matrix, OssiGraft Prime™. The launch of this innovative product represents a significant leap forward in orthopedic biologics, offering surgeons and patients meaningful advantages compared to traditional options.

Ossium Health, an innovative bioengineering company that established a first-of-its-kind bone marrow banking platform, today announced the appointment of Lauren Barnes to its Board of Directors. Barnes brings extensive experience in healthcare product commercialization, significantly bolstering Ossium’s capacity to drive growth and deliver life-changing solutions for patients suffering from hematologic diseases, organ transplant rejection, and musculoskeletal defects.

Ossium Health, a bioengineering company leveraging stem cell science to develop treatments for diseases of the blood and immune systems, has been named as a winner of the Inc. 2023 Best in Business award. This award recognizes dynamic companies that made an extraordinary positive impact on their communities, their industries, the environment, or society as a whole in the past year. Ossium was named a winner in two categories: Health Products, which honors companies producing healthcare products, and Lean and Mean, which honors companies with annual gross revenues under $5m.

Ossium Health, a bioengineering company developing the world's first bank of organ donor bone marrow, and the National Marrow Donor Program® (NMDP)/Be The Match®, a global leader working to save lives through cellular therapy, today announced their partnership to expand access to vital bone marrow and accelerate the industry’s ability to make bone marrow transplants accessible at scale.

Ossium Health, a bioengineering company developing the world's first bank of on-demand bone marrow, today announced a $52 million Series C funding round. The round was led by CPMG, with participation from Vivo Capital, First Round Capital, Manta Ray Ventures, Alumni Ventures, and Asahi Kasei. The company is improving the health, vitality, and longevity of human beings through bioengineering and will deploy this funding to dramatically grow its proprietary bone marrow bank, build on existing clinical trials, and accelerate new product development.